For the ninth consecutive year, the independent French medical journal Prescrire has published its review of "Drugs to avoid, in the name of better patient care". This report identifies drugs whose dangers clearly outweigh their benefits and which ought to be avoided. The aim is to help healthcare professionals and patients choose high-quality treatments, first to do no harm to patients, and to minimise adverse effects.
Prescrire's assessment of the harm-benefit balance of a drug in a given situation is based on a rigorous, collective procedure that includes a systematic and reproducible literature search, identification of patient-relevant outcomes, prioritisation of the supporting data based on the strength of evidence, comparison with standard treatments, and an analysis of both known and potential adverse effects.
The 2021 update, published in the December 2020 issue of the French edition, covers drugs analysed over a period of 11 years, from 2010 through 2020, and includes 112 drugs (of which 93 are currently on the market in France) that are more harmful than beneficial in all the indications for which they have been authorised in France or in the European Union.
The updated review will be published in English in the February 2021 edition of Prescrire International.
The French version is available for free download below.
©Prescrire 1 December 2020
Source: "Pour mieux soigner, des médicaments à écarter : bilan 2021" Rev Prescrire 2020; 40 (446) : 929-941. (pdf in French, free)
Enjoy full access to Prescrire International, and support independent information
|